Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients (COVELEC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04414059|
Recruitment Status : Not yet recruiting
First Posted : June 4, 2020
Last Update Posted : October 26, 2020
|Condition or disease|
|SARS-CoV 2 Hospitalisation-Associated Infection|
In late December 2019, an outbreak of an emerging respiratory disease (COVID-19) caused by a novel coronavirus named SARS-CoV-2 began in Wuhan City, Hubei Province, China and quickly spread in a substantial number of countries. The epidemic was declared a pandemic by the Word Health Organization (WHO) on 12 March 2020. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption.
Both clinical and epidemiological features of patients with COVID-19 have recently been reported, demonstrating that the SARS-CoV-2 infection can be asymptomatic in some cases or symptomatic in others. Symptomatology usually begins as mild with fever, fatigue, dry cough, and occasional dyspnea. In a minority of patients, a sudden onset of severe symptoms may develop 5-8 days into the illness including shortness of breath, pneumonitis, acute respiratory distress syndrome (ARDS) and multi organ dysfunction leading to intensive care unit (ICU) admission and high mortality. In some cases, accumulating evidence suggests that severe COVID-19 symptoms could be due to a cytokine storm syndrome. As of May 3rd 2020, the virus had infected 3,349,786 patients worldwide with more than 238,600 deaths, more often among older patients with underlying health conditions.
With caseloads overwhelming hospitals and resources stretched thin in this surging pandemic (high demand for oxygen, prolonged ventilation and even extracorporeal membrane oxygenation (ECMO), particularly for patients with acute ARDS), there is an urgent need to enhance clinical skills in order to predict from the many mild cases those few that will progress to critical illness allowing a more efficient resource allocation and clinical management.
Several studies on patient blood have described features that were most predictive of ARDS. These studies showed that severe cases, compared to mild cases, had : 1) older age; 2) abnormalities in chest scanning (CT) such as multiple patch-like shadows and ground glass opacity; 3) organ and coagulation dysfunction with a higher levels of alanine aminotransferase (ALT), lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer; 4) as well as markedly higher levels of immunological characteristics such as IL-2R, IL-6, IL-10, and TNF- α ; 5) and an absolute T lymphocytes (CD4+ and CD8+ T cells) number markedly lower in nearly all severe cases. These observations suggest that severity and mortality might be due to virally driven systemic hyperinflammation secondary to failure of the immune response to control infection (as shown for other viruses).
With this study we want to caracterize the predictive performance of the serum inflammation profiles by protein electrophoresis, associated with clinical, radiological and biological risk factors for worsening. This study is a prospective, observational study conducted on patients hospitalized for an infection with the SARS-CoV-2 virus.
|Study Type :||Observational|
|Estimated Enrollment :||155 participants|
|Official Title:||Complications Risk Factors in Patients Hospitalized for COVID-19 Infection: Role of Proteins Electrophoresis|
|Estimated Study Start Date :||March 2021|
|Estimated Primary Completion Date :||June 2021|
|Estimated Study Completion Date :||August 2021|
- Complications onset [ Time Frame: Up to 3 weeks ]hospitalisation in Intensive Care Unit OR Oxygen needs > 6 L/min OR death whatever the cause
- Risk value associated with each risk factor as identified at the end of the main study analysis [ Time Frame: Up to 3 weeks ]Risk quantification
- Predictive performance and risk associated with each individual protein fraction [ Time Frame: Up to 3 weeks ]Correlation between complications onset (as defined by hospitalisation in Intensive Care Unit OR Oxygen needs > 6 L/min OR death whatever the cause) and individual protein fraction value
- Intra-patient kinetics evolution of the electrophoresis curves [ Time Frame: Up to 3 weeks ]Evolution over time of the serum quantity of each individual protein fraction (6 fractions studied)
- Intra-patient kinetics evolution of biological risk factors [ Time Frame: Up to 3 weeks ]Evolution over time of the serum quantity of each biological risk factor (as defined for the study)
- Inter-expert reproducibility analysis of electrophoretic inflammatory profiles centrally reviewed [ Time Frame: After study completion, estimated 10 months after first patient enrolled ]Central review of each serum protein electrophoresis curve
- Contribution of urinary electrophoresis inflammation profiles in the interpretation of serum electrophoresis curves [ Time Frame: Up to 3 weeks ]Urine samples at admission, every 4 days and at complications onset
- Exploratory biological objective: Definition of a more detailed electrophoretic inflammatory profile [ Time Frame: After study completion, estimated 10 months after first patient enrolled ]Biobank with serum samples for the implementation, at the end of the study, of a high-resolution capillary electrophoresis technique enabling each serum protein to be viewed individually
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04414059
|Contact: Shahnaz KLOUCHE||(0)1 58 56 41 71 ext +email@example.com|
|Contact: Johanna MIMOUNI||(0)1 56 69 16 45 ext +firstname.lastname@example.org|
|Clinique de l'Estrée|
|Contact: Stéphane DI MASCIO, MD (0)1 49 71 71 71 ext +33 email@example.com|
|Principal Investigator: Stephane DI MASCIO, MD|